Welcome to our dedicated page for COMPUGEN SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COMPUGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COMPUGEN's regulatory disclosures and financial reporting.
Compugen Ltd. convenes its 2026 annual shareholder meeting for September 10, 2026 at 6:00 PM (Israel time), with a record date of July 27, 2026. Shareholders will vote on electing eight directors, approving an amended compensation policy and re-appointing Kost Forer Gabbay & Kasierer (EY Global) as independent auditor for 2026.
The proxy details Israeli voting mechanics, including a Special Majority requirement for the compensation policy, and outlines proxy, electronic and in-person voting options. As of July 30, 2026 there were 94,727,926 Ordinary Shares outstanding, with options, RSUs and reserved shares representing approximately 9.3% of fully diluted capital. 2025 fees to the auditor totaled $236,500.
Compugen Ltd. reported results for the second quarter and first half of 2026 together with updates on its immuno-oncology pipeline. The MAIA-ovarian randomized adaptive platform trial of COM701 as maintenance monotherapy in relapsed platinum-sensitive ovarian cancer is progressing, with an interim analysis of median progression-free survival expected by the first quarter of 2027. Partner AstraZeneca reported a first overall survival readout for rilvegostomig in first-line biliary tract cancer and continues a broad Phase 3 program, while Gilead-partnered GS-0321 remains in an ongoing Phase 1 trial.
For the six months ended June 30, 2026, revenue was $4,778 (U.S. dollars in thousands) versus $3,541 (U.S. dollars in thousands) a year earlier, mainly recognition of Gilead upfront and IND milestone payments. Research and development expenses rose to $13,245 (U.S. dollars in thousands), contributing to an operating loss of $17,854 (U.S. dollars in thousands) and a net loss of $14,675 (U.S. dollars in thousands), or $0.16 per basic and diluted share. Cash, cash equivalents, short-term bank deposits and marketable securities totaled about $125.3 million, and the company states this cash runway is expected to fund operations into 2029.
COMPUGEN LTD SVP, Business Development Zurit Levine reported equity awards. The insider received 18000.0000 restricted stock units and 24000.0000 share options at an exercise price of 2.2600 per share, each vesting 25% on September 30, 2027 and the remainder in 12 equal quarterly installments, contingent on continued service, resulting in 47375.0000 ordinary shares held directly.
Compugen Ltd granted Chief Financial Officer David Silberman 19,500 restricted stock units and 26,000 share options on July 29, 2026. The options have an exercise price of 2.2600 and expire on July 29, 2036. Both awards vest 25% on September 30, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, Silberman directly holds 55,000 ordinary shares and 26,000 options.
Compugen Ltd President and CEO Ophir Eran received a grant of 200000.0000 share options for ordinary shares on 2026-07-29. The options carry a $2.2600 exercise price and expire on 2036-07-29. They vest 25% on September 30, 2027, then in 12 equal quarterly installments, subject to continued service.
Compugen Ltd reported that director Anat Cohen-Dayag received a grant of 100,000 share options to purchase Ordinary Shares at an exercise price of $2.2600 per share. The option expires on 2036-07-29 and vests 25% on September 30, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued service. Following this award, the reported derivative holdings from this grant total 100,000 options.
Compugen director Eran Perry reported two equity awards dated 2026-07-29: a grant of 10,000 share options to buy ordinary shares at an exercise price of $2.2600 expiring 2036-07-29, and an award of 7,500 restricted stock units. Both grants vest 25% on October 1, 2027, with the balance vesting in 12 equal quarterly installments, subject to continued service. Following these awards, Perry directly holds 17,500 ordinary shares and options for 10,000 shares.
Compugen Ltd granted Chief Operating Officer Pierre Ferre 70,000 share options over ordinary shares at an exercise price of $4.00 per share, expiring on July 29, 2036. The option vests 25% on September 30, 2027, with the remainder vesting in 12 equal quarterly installments, subject to his continued service.
Compugen Ltd (CGEN) reported equity awards to executive Kredo Russo Sharon, SVP, Research & Discovery. On July 29, 2026, she received 18,000 restricted stock units representing ordinary shares and options for 24,000 ordinary shares at a $2.26 exercise price, expiring July 29, 2036. Both awards vest 25% on September 30, 2027, with the balance vesting in 12 equal quarterly installments, subject to continued service. Following the RSU grant, 37,500 ordinary shares are reported as directly owned.
Livnat Savitzky Kinneret reported acquisition or exercise transactions in this Form 4 filing.
Compugen director Livnat Savitzky Kinneret received equity awards on July 29, 2026, including options to purchase 10,000 Ordinary Shares at $2.26 per share expiring July 29, 2036, and 7,500 restricted stock units. Both awards vest 25% on October 1, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, her direct holdings of Ordinary Shares are reported as 20,850, and she also holds the 10,000-share option grant.